Can we treat cancer for a dollar a day? Guidelines for low-income countries

New England Journal of Medicine

Volumn 363, Issue 9, 2010, Pages 801-803

  Kerr, David J ^a   Midgley, Rachel ^b  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; FUNDING; HEALTH CARE; HEALTH CARE SYSTEM; HUMAN; KENYA; LOWEST INCOME GROUP; NATIONAL HEALTH SERVICE; NEOPLASM; NUTRITIONAL STATUS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

EID: 77956052538     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1002812     Document Type: Short Survey

References (5)

1. Lingwood R, Boyle P, Milburn A, et al. The challenge of cancer control in Africa. Nat Rev Cancer 2008;8:398-403.
2. Kerr F, Kerr DJ. Do we bear any moral responsibility for improving cancer care in Africa? Ann Oncol 2006;17:1730-1.
3. Tan-Torres ET, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
4. Groot MT, Baltussen R, Uyl-de Groot C, Anderson BA, Hortobágyi GN. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J 2006; 12:Suppl 1:S81-S90.
5. CanTreat International. Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic? Ann Oncol 2010;21:680-2.